MAK Capital Reports 12.6% Stake in Autolus Therapeutics plc (AUTL)

On May 15, 2026, MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman filed a Schedule 13G/A disclosing a significant ownership stake in Autolus Therapeutics plc (AUTL). The reporting persons reported beneficial ownership of 33,621,487 American Depositary Shares (ADS), where each ADS represents one ordinary share. This position represents a 12.6% ownership interest in the company, based on 266,155,786 ordinary shares outstanding as of May 13, 2026. The filing indicates that the reporting persons share voting and dispositive power over the entire 33,621,487 shares. This 13G/A amendment highlights a substantial increase from previously reported holdings, which were listed as zero in prior snapshots. The securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. MAK Capital Fund LP is a Bermuda limited partnership, while Michael A. Kaufman, the managing member, is a U.S. citizen. The principal business office for the primary entities is located in New York.